Literature DB >> 26308599

Decreased Interferon Alpha/Beta Signature Associated with Human Lung Tumorigenesis.

Run Tong1, Lin Feng1, Lei Zhang2, Jianzhi Zhang3, Yousheng Mao4, Kaitai Zhang1, Yanning Gao1, Guiqi Wang2, Shujun Cheng1.   

Abstract

Accumulating evidence suggests that interferon (IFN) alpha/beta are involved in antitumor immunity and cancer immunoediting, but information on the antitumor effects of IFN alpha/beta in lung cancer is limited. In our study, we elucidated the IFN alpha/beta signature during both human fetal lung development and lung tumorigenesis. Our findings indicated gradual upregulation in the IFN alpha/beta signature during human fetal lung development. In addition, this signature was progressively downregulated in normal human airway epithelial cells from lung cancer patients, in immortalized human bronchial epithelial cell lines from later passages, in late-stage lung squamous cell carcinoma (LSCC) tissues, and in LSCC tissues exhibiting lymph node metastasis. Therefore, from its earliest stages, lung tumorigenesis may be associated with a decreased IFN alpha/beta signature. This association may provide insight to guide the detection of high-risk lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26308599      PMCID: PMC4683557          DOI: 10.1089/jir.2015.0061

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  30 in total

1.  Identification of differentially expressed genes in immortalized human bronchial epithelial cell line as a model for in vitro study of lung carcinogenesis.

Authors:  Qian An; Manuela Pacyna-Gengelbach; Karsten Schlüns; Nicole Deutschmann; Suping Guo; Yanning Gao; Jianjun Zhang; Shujun Cheng; Iver Petersen
Journal:  Int J Cancer       Date:  2003-01-10       Impact factor: 7.396

Review 2.  Review: IFN-alpha/beta receptor interactions to biologic outcomes: understanding the circuitry.

Authors:  Melissa M Brierley; Eleanor N Fish
Journal:  J Interferon Cytokine Res       Date:  2002-08       Impact factor: 2.607

3.  Molecular characteristics of non-small cell lung cancer.

Authors:  M Nacht; T Dracheva; Y Gao; T Fujii; Y Chen; A Player; V Akmaev; B Cook; M Dufault; M Zhang; W Zhang; M Guo; J Curran; S Han; D Sidransky; K Buetow; S L Madden; J Jen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Integration of SV40 at 12q23 in SV40-immortalized human bronchial epithelial cells.

Authors:  Y J Lu; X Y Dong; S P Guo; Y Ke; S J Cheng
Journal:  Carcinogenesis       Date:  1996-09       Impact factor: 4.944

5.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.

Authors:  Y A Sidky; E C Borden
Journal:  Cancer Res       Date:  1987-10-01       Impact factor: 12.701

6.  Molecular and cytogenetic alterations in early stage of carcinogenesis of human lung.

Authors:  S Cheng; Y Gao; X Dong; Y Lu; Q An; T Tong; Y Wang
Journal:  Cancer Lett       Date:  2001-01       Impact factor: 8.679

7.  Interferon-alpha and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer--a feasibility study.

Authors:  T Ruotsalainen; M Halme; O P Isokangas; S Pyrhönen; M Mäntylä; M Pekonen; S Sarna; H Joensuu; K Mattson
Journal:  Anticancer Drugs       Date:  2000-02       Impact factor: 2.248

8.  Timely and spatially regulated maturation of B and T cell repertoire during human fetal development.

Authors:  Erez Rechavi; Atar Lev; Yu Nee Lee; Amos J Simon; Yoav Yinon; Schlomo Lipitz; Ninette Amariglio; Boaz Weisz; Luigi D Notarangelo; Raz Somech
Journal:  Sci Transl Med       Date:  2015-02-25       Impact factor: 17.956

9.  Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence.

Authors:  Akinori Takaoka; Sumio Hayakawa; Hideyuki Yanai; Dagmar Stoiber; Hideo Negishi; Hideaki Kikuchi; Shigeru Sasaki; Kohzoh Imai; Tsukasa Shibue; Kenya Honda; Tadatsugu Taniguchi
Journal:  Nature       Date:  2003-07-31       Impact factor: 49.962

Review 10.  Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.

Authors:  M Chawla-Sarkar; D J Lindner; Y-F Liu; B R Williams; G C Sen; R H Silverman; E C Borden
Journal:  Apoptosis       Date:  2003-06       Impact factor: 4.677

View more
  6 in total

1.  Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.

Authors:  Yukitomo Ishi; Yongzhan Zhang; Ali Zhang; Takahiro Sasaki; Andrea Piunti; Amreena Suri; Jun Watanabe; Kouki Abe; Xingyao He; Hiroaki Katagi; Pankaj Bhalla; Manabu Natsumeda; Lihua Zou; Ali Shilatifard; Rintaro Hashizume
Journal:  Mol Cancer Ther       Date:  2022-05-04       Impact factor: 6.009

2.  Villi development core-related gene expression associated with lung squamous cancer prognosis.

Authors:  Liyuan Yin; Yonggang Wang; Guangzhi Ma; Yunfu Deng; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

3.  The bioinformatics analysis of RIOX2 gene in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Bingqing Sun; Hongwen Zhao
Journal:  PLoS One       Date:  2021-12-02       Impact factor: 3.240

4.  Identification of Immune Subtypes of Lung Squamous Cell Carcinoma by Integrative Genome-Scale Analysis.

Authors:  Liyuan Yin; Wen Zhang; Dan Pu; Xiaoqian Zhai; Yiyun Lin; Qiang Wu; Tangel Chang; Jia Hu; Yan Li; Qinghua Zhou
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

5.  Increased PPARD Expression May Play a Protective Role in Human Lung Adenocarcinoma and Squamous Cell Carcinoma.

Authors:  Yong Zhu; Yedong Mi; Zhonghua Qin; Xuewei Jiang; Yibo Shan; Kamil Kural; Guiping Yu
Journal:  PPAR Res       Date:  2022-03-15       Impact factor: 4.964

6.  Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.

Authors:  Ping Li; Lei Zhang; Xuexin Yu; Run Tong; Xuebing Di; Yousheng Mao; Yanning Gao; Kaitai Zhang; Lin Feng; Shujun Cheng
Journal:  Cancer Sci       Date:  2017-12-27       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.